tiprankstipranks
Advertisement
Advertisement

AU:RAD Stock Latest News

Radiopharm Theranostics reshapes finance and governance team under Acclime partnership
Company AnnouncementsRadiopharm Theranostics reshapes finance and governance team under Acclime partnership
3d ago
RAD
Radiopharm Theranostics advances radiopharmaceutical pipeline with key trial milestones
PremiumCompany Announcements
Radiopharm Theranostics advances radiopharmaceutical pipeline with key trial milestones
11d ago
RAD
Radiopharm announces new data from Phase 0/1 HEAT trial
PremiumThe Fly
Radiopharm announces new data from Phase 0/1 HEAT trial
14d ago
RADX
Radiopharm Unveils Encouraging First-in-Human Data for HER2 Radiopharmaceutical 177Lu-RAD202
PremiumCompany Announcements
Radiopharm Unveils Encouraging First-in-Human Data for HER2 Radiopharmaceutical 177Lu-RAD202
14d ago
RAD
Radiopharm completes U.S. Phase 2b enrolment for RAD 101 brain metastasis imaging trial
PremiumCompany Announcements
Radiopharm completes U.S. Phase 2b enrolment for RAD 101 brain metastasis imaging trial
18d ago
RAD
Radiopharm gets DSMC recommendation to advance 177Lu-RAD202 to next dose
PremiumThe FlyRadiopharm gets DSMC recommendation to advance 177Lu-RAD202 to next dose
26d ago
RADX
Radiopharm Director Adjusts Share and Option Holdings
Premium
Company Announcements
Radiopharm Director Adjusts Share and Option Holdings
1M ago
RAD
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
1M ago
RADX
SMMT
Buy Rating on RADX Driven by Promising RAD 101 Phase 2b Imaging Data and Clear 2026 Clinical Milestones
PremiumRatings
Buy Rating on RADX Driven by Promising RAD 101 Phase 2b Imaging Data and Clear 2026 Clinical Milestones
1M ago
RADX
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
1M ago
RADX
Radiopharm’s RAD101 Hits 90% Concordance in Phase 2b Brain Metastases Trial
PremiumCompany Announcements
Radiopharm’s RAD101 Hits 90% Concordance in Phase 2b Brain Metastases Trial
1M ago
RAD
Radiopharm Theranostics to spotlight oncology pipeline at NWR Virtual Healthcare Conference
PremiumCompany Announcements
Radiopharm Theranostics to spotlight oncology pipeline at NWR Virtual Healthcare Conference
2M ago
RAD
Radiopharm Theranostics Narrows Asset Base as Half-Year Loss Widens, Increases Stake in MD Anderson JV
PremiumCompany AnnouncementsRadiopharm Theranostics Narrows Asset Base as Half-Year Loss Widens, Increases Stake in MD Anderson JV
2M ago
RAD
Radiopharm doses first patient in Phase 1/2a study of BetaBart
Premium
The Fly
Radiopharm doses first patient in Phase 1/2a study of BetaBart
2M ago
RADX
Radiopharm’s New 161Tb-RAD402 Trial Puts AU:RAD in Focus for Prostate Cancer Investors
Premium
Company Announcements
Radiopharm’s New 161Tb-RAD402 Trial Puts AU:RAD in Focus for Prostate Cancer Investors
3M ago
RAD
Radiopharm reports cash balance of $34.52M as of December 31
PremiumThe Fly
Radiopharm reports cash balance of $34.52M as of December 31
3M ago
RADX
Radiopharm Theranostics Posts Solid Cash Runway and Positive Interim Data for Lead Brain Metastases Imaging Agent
PremiumCompany Announcements
Radiopharm Theranostics Posts Solid Cash Runway and Positive Interim Data for Lead Brain Metastases Imaging Agent
3M ago
RAD
Radiopharm’s New Phase 1 Imaging Trial Puts LRRC15-Targeted Radiotherapy in Focus
PremiumCompany Announcements
Radiopharm’s New Phase 1 Imaging Trial Puts LRRC15-Targeted Radiotherapy in Focus
3M ago
RAD
Radiopharm increases ownership in Radiopharm Ventures to 87.5%
PremiumThe Fly
Radiopharm increases ownership in Radiopharm Ventures to 87.5%
4M ago
RADX
Radiopharm Theranostics Options Lapse, Trimming Potential Dilution
PremiumCompany AnnouncementsRadiopharm Theranostics Options Lapse, Trimming Potential Dilution
4M ago
RAD
Radiopharm Theranostics Increases Director Paul Hopper’s Option Holdings After AGM Approval
Premium
Company Announcements
Radiopharm Theranostics Increases Director Paul Hopper’s Option Holdings After AGM Approval
5M ago
RAD
Radiopharm Theranostics Increases Director Ian Turner’s Option Holdings After Shareholder Approval
Premium
Company Announcements
Radiopharm Theranostics Increases Director Ian Turner’s Option Holdings After Shareholder Approval
5M ago
RAD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >